SELLAS Life Sciences (SLS) Equity Ratio (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Equity Ratio data on file, last reported at 0.94 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.94, up 18.47% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.94 (up 18.47% YoY), and the FY2025 annual result was 0.9, up 85.72% from the prior year.
• Equity Ratio grew to 0.94 in Q1 2026 per SLS's latest filing, from 0.9 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.94 in Q1 2026 and troughed at 1.28 in Q4 2023.
• A 5-year average of 0.38 and a median of 0.48 in 2022 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2023 and 2025: Equity Ratio tumbled 653.7% in 2023, then jumped 320.11% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.23 in 2022, then plunged by 653.7% to 1.28 in 2023, then jumped by 137.98% to 0.49 in 2024, then surged by 85.72% to 0.9 in 2025, then rose by 4.0% to 0.94 in 2026.
• Business Quant data shows SLS's Equity Ratio at 0.94 in Q1 2026, 0.9 in Q4 2025, and 0.89 in Q3 2025.